Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics
XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra general meeting on October 4, and a notice will be sent out separately.“We are incredibly pleased to be able attract such dedicated life science professionals as David and Stephen to the board. They will definitely add valuable knowledge to XNK.”, said Lena Degling Wikingsson, Chairman of the Board. Dr. Berglund, M.D., Ph.D., M.B.A., is an Associate Professor of Immunology at Uppsala University